Is THER or ORCC a better dividend investment in 2026?

THER currently yields 2000000.00% with a 5% 5-year dividend growth rate. ORCC yields 9.79% with 5% growth. The better choice depends on your goal: THER offers higher current income.

What is the dividend yield difference between THER and ORCC?

THER has a forward dividend yield of 2000000.00% ($2.00/share annually). ORCC yields 9.79% ($1.32/share annually). The yield gap is 1999990.21 percentage points.

Home › Compare › THER vs ORCC

THER vs ORCC: Dividend Comparison 2026

THER yields 2000000.00% · ORCC yields 9.79%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 THER wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

THER

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full THER calculator →

ORCC

● Live price

9.79%

Share price

$13.48

Annual div

$1.32

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$21.4K

Annual income

$1.04

Full ORCC calculator →

Portfolio growth — THER vs ORCC

📍 THER pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	THER	ORCC
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, THER + ORCC cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

THER pays

ORCC pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THER

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

ORCC

Annual income on $10K today (after 15% tax)

$832.34/yr

After 10yr DRIP, annual income (after tax)

$0.88/yr

At 15% tax rate, THER beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THER + ORCC for your $10,000?

THER: 50%ORCC: 50%

100% ORCC50/50100% THER

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

THER

No analyst data

Altman Z

-71.3

Piotroski

2/9

ORCC

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$16.00

+18.7% upside vs current

Range: $16.00 — $16.00

Altman Z

0.5

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THER buys

ORCC buys

No recent congressional trades found for THER or ORCC in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricTHERORCC

Forward yield	2000000.00% ✓	9.79%
Annual dividend / share	$2.00 ✓	$1.32
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0% ✓	-50%
Portfolio after 10y	$4.879226400974806e+39M	$21.4K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$1.04
Total dividends collected	$4.879195005460081e+39M ✓	$1.0K
Payment frequency	quarterly	quarterly
Sector	Stock	BDC

Year-by-year: THER vs ORCC ($10,000, DRIP)

Year	THER Portfolio	THER Income/yr	ORCC Portfolio	ORCC Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$11,190	$489.61	+$200.00M → THER
2	$3,738,731,768,458	$3,738,517,757,009.35	$12,229	$256.01	+$3738731.76M → THER
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$13,216	$130.74	+$65315062866.92M → THER
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$14,207	$66.02	+$1066400830062625.00M → THER
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$15,234	$33.17	+$16272182796453826560.00M → THER
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$16,317	$16.62	+$2.3205424011366188e+23M → THER
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$17,468	$8.32	+$3.0927990661046884e+27M → THER
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$18,695	$4.16	+$3.8524105697352695e+31M → THER
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$20,006	$2.08	+$4.484688260147987e+35M → THER
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$21,407	$1.04	+$4.879226400974806e+39M → THER

THER vs ORCC: Complete Analysis 2026

THER — Stock

Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. The company through its patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. The company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. The company is headquartered in Golden, Colorado.

Full THER Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →

📬

Get this THER vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THER vs SCHD THER vs JEPI THER vs O THER vs KO THER vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.